No Data
No Data
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18
BioCryst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 5, 2025
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $11
Executive Reshuffles: CVS, NNDM, and DBX
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $11
Express News | RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $11 Price Target